CDG Therapeutics was founded by University of Illinois, Chicago College of Medicine professors following the discovery that certain therapeutic peptides derived from the cupredoxin family of bacterial and plant proteins can be used as novel anti-cancer agents. CDG holds the exclusive worldwide license with commercialization rights of the cupredoxin family of proteins as well as the cell-penetrating peptides (CPP) derived from the entire molecule of these proteins.
CDG has an extensive intellectual property portfolio which includes 11 issued patents and 25 pending/provisional patents and PCT applications.
In addition to several NIH and NCI grants, the company's research and development is funded through private equity investments.
CDG was incorporated in the State of Delaware in May 2001.
Founder Tapas K. Das Gupta, M.D., Ph.D., D.Sc, is an internationally recognized surgical oncologist and Department Head in the Department of Surgical Oncology at the University of Illinois at Chicago. As a founder and Chairman Emeritus of CDG, he continues to serve as the guiding light in clinical and basic science research and development.